الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>MS049

MS049

رقم الكتالوجGC36656

MS049 هو مثبط مزدوج فعال وانتقائي وخلوي لـ PRMT4 و PRMT6 مع IC50s من 34 نانومتر و 43 نانومتر ، على التوالييقلل MS049 من مستويات Med12me2a و H3R2me2a في خلايا HEK293MS049 غير سام ولا يؤثر على نمو خلايا HEK293

Products are for research use only. Not for human use. We do not sell to patients.

MS049 التركيب الكيميائي

Cas No.: 1502816-23-0

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
67٫00
متوفر
5mg
61٫00
متوفر
10mg
102٫00
متوفر
25mg
222٫00
متوفر
50mg
408٫00
متوفر
100mg
742٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC 50 of 34 nM and 43 nM respectively.target: PRMT4, PRMT6;IC 50: 34 nM (PRMT4 ), 43 nM (PRMT6 );In vitro: MS 049 reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner. MS 049 treatment (72 h exposure) inhibits endogenous PRMT4 methyltransferase activity in a concentration dependent manner resulting in reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC50 = 1.4 ± 0.1 μM (n = 3)) in HEK293 cells.

[1]. Shen Y et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem. 2016 Sep 15.

مراجعات

Review for MS049

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MS049

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.